← Leaderboards
Ian Frank
University Of Pennsylvania
$25,757,892
Attributed
$40,231,683
Total exposure
22
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.2M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$40,231,683 · 22
By mechanism
UM1$28,947,582 · 1
P30$7,328,088 · 4
M01$3,956,013 · 17
Top collaborators
- Pablo Tebas13 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Susan R. Weiss$24,407,392
- Alexander Ploss$13,732,497
- Pablo Tebas$38,856,630
- Robert H. Silverman$18,272,403
- George M Shaw$56,045,759
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectAids TherapyHiv InfectionsHuman Therapy EvaluationCombination ChemotherapyAntiaids AgentClinical TrialsDrug Screening /EvaluationProtease InhibitorAntiviral AgentsAdultResearch PersonnelAdolescentMentorsFacultySciencePennsylvaniaPhiladelphiaBehavioral ResearchCaringUniversitiesChildhoodChild
Grant awards (105)
University of Pennsylvania HIV Clinical Trials Unit$2,761,412
UM1 · FY2025 · AI · contact PI
University of Pennsylvania HIV Clinical Trials Unit$2,946,326
UM1 · FY2024 · AI · contact PI
University of Pennsylvania HIV Clinical Trials Unit$3,487,235
UM1 · FY2023 · AI · contact PI
Clinical Core$368,860
P30 · FY2023 · AI · contact PI
University of Pennsylvania HIV Clinical Trials Unit$3,313,023
UM1 · FY2022 · AI · contact PI
Clinical Core$325,449
P30 · FY2022 · AI · contact PI
University of Pennsylvania HIV Clinical Trials Unit$3,690,931
UM1 · FY2021 · AI · contact PI
Clinical Core$554,022
P30 · FY2021 · AI · contact PI
Philadelphia HIV Therapeutics and Prevention Clinical Trials Unit$2,464,363
UM1 · FY2020 · AI
Clinical Core$375,530
P30 · FY2020 · AI · contact PI
Philadelphia HIV Therapeutics and Prevention Clinical Trials Unit$299,668
UM1 · FY2020 · AI
Philadelphia HIV Therapeutics and Prevention Clinical Trials Unit$2,942,898
UM1 · FY2019 · AI
Clinical Core$374,763
P30 · FY2019 · AI · contact PI
Philadelphia HIV Therapeutics and Prevention Clinical Trials Unit$1,215,815
UM1 · FY2018 · AI
Clinical Core$360,038
P30 · FY2018 · AI · contact PI
Philadelphia HIV Therapeutics and Prevention Clinical Trials Unit$1,215,815
UM1 · FY2017 · AI
Clinical Core$359,538
P30 · FY2017 · AI · contact PI
Philadelphia HIV Therapeutics and Prevention Clinical Trials Unit$1,230,515
UM1 · FY2016 · AI
Clinical Core$364,216
P30 · FY2016 · AI · contact PI
Philadelphia HIV Therapeutics and Prevention Clinical Trials Unit$1,315,740
UM1 · FY2015 · AI
Clinical Core$365,125
P30 · FY2015 · AI · contact PI
Philadelphia HIV Therapeutics and Prevention Clinical Trials Unit$2,063,841
UM1 · FY2014 · AI
Clinical Core$376,201
P30 · FY2014 · AI · contact PI
Clinical$312,794
P30 · FY2013 · AI · contact PI
Clinical$370,141
P30 · FY2012 · AI · contact PI
Clinical$368,408
P30 · FY2011 · AI · contact PI
Clinical$363,432
P30 · FY2010 · AI · contact PI
Clinical$336,859
P30 · FY2009 · AI · contact PI
Core--Clinical Facility$368,524
P30 · FY2008 · AI · contact PI
Core--Clinical Facility$427,324
P30 · FY2007 · AI · contact PI
Core--Clinical Facility$329,706
P30 · FY2006 · AI · contact PI
Core--Clinical Facility$320,231
P30 · FY2005 · AI
SUBJECTS WITH PERSISTENT CD4+ CELL COUNTS GREATER THAN 500 CELLS/MM3$90,245
M01 · FY2005 · RR
THE EFFECTS OF OMP,APV AND ATV IN HEALTHY SUBJECTS VS HIV SUBJECTS$28,498
M01 · FY2005 · RR
EFFECT OF PERIPHERAL FAT WASTING WITH A THYMIDINE ANALOGUE SUBSTITUTION$17,415
M01 · FY2005 · RR
METFORMIN AND ROSIGLITAZONE, ALONE OR IN COMBINATION IN HIV SUBJECTS$11,084
M01 · FY2005 · RR
ACTG: PREDICTORS OF PROGRESSION OFF ART$10,290
M01 · FY2005 · RR
Core--Clinical Facility$306,927
P30 · FY2004 · AI
Subjects with Persistent CD4+ Cell Counts Greater Than 500 Cells/mm3$182,119
M01 · FY2004 · RR
PREDICTORS OF PROGRESSION OF ART$21,176
M01 · FY2004 · RR
METFORMIN AND ROSIGLITAZONE- HYPERINSULINEMIA &ELEVATED WAIST/HIP RATIO$5,929
M01 · FY2004 · RR
PERIPHERAL FAT WASTING WITH THYMIDINE ANALOGUE SUBSTITUTION/CHANGE$3,387
M01 · FY2004 · RR
LODENOSINE (FDDA) COMBINED W STAVUDINE &INDINAVIR$124,146
M01 · FY2002 · RR
ACTG 307--HYDROXUREA VS HYDROXUREA + DDI VS DDI$124,146
M01 · FY2002 · RR
GS-417: EFFICACY OF ADEFOVIR DIPIVOXIL AT 2 DOSE LEVELS IN TRIPLE COMBINATION$124,146
M01 · FY2002 · RR
ACTG 364--COMPARISON OF THE VIROLOGIC EFFICACY OF NELFINAVIR$124,146
M01 · FY2002 · RR
ACTG374: STUDY 1) 141W94 &VX 478 PLUS 3TC PLUS ZDV OR 2) INDINAVIR +$124,146
M01 · FY2002 · RR
ACTG 325: RECOMBINANT HUMAN INTERLEUKIN 12 (RHIL 12) IN HIV INFECTED SUBJECTS$124,146
M01 · FY2002 · RR
ACTG 384: STUDY OF PROTEASE INHIBITOR AND/OR NON NUCLEOSIDE REVERSE$124,146
M01 · FY2002 · RR
ACTG 5025: HYDROXYUREA IN PTS ON POTENT ANTIRETROVIRAL$124,146
M01 · FY2002 · RR
ACTG A5039: HIV RNA SUPPRESSION DDL/D4T/HU VS DDL/D4TEPV VS CONTINUING PROTEASE$124,146
M01 · FY2002 · RR
ACTG A5039: HIV RNA SUPPRESSION DDL/D4T/HU VS DDL/D4TEPV VS CONTINUING PROTEASE$124,146
M01 · FY2001 · RR
LODENOSINE (FDDA) COMBINED W STAVUDINE &INDINAVIR$124,146
M01 · FY2001 · RR
ACTG 5025: HYDROXYUREA IN PTS ON POTENT ANTIRETROVIRAL$124,146
M01 · FY2001 · RR
ACTG 384: STUDY OF PROTEASE INHIBITOR AND/OR NON NUCLEOSIDE REVERSE$124,146
M01 · FY2001 · RR
ACTG 325: RECOMBINANT HUMAN INTERLEUKIN 12 (RHIL 12) IN HIV INFECTED SUBJECTS$124,146
M01 · FY2001 · RR
ACTG374: STUDY 1) 141W94 &VX 478 PLUS 3TC PLUS ZDV OR 2) INDINAVIR +$124,146
M01 · FY2001 · RR
ACTG 364--COMPARISON OF THE VIROLOGIC EFFICACY OF NELFINAVIR$124,146
M01 · FY2001 · RR
GS-417: EFFICACY OF ADEFOVIR DIPIVOXIL AT 2 DOSE LEVELS IN TRIPLE COMBINATION$124,146
M01 · FY2001 · RR
ACTG 307--HYDROXUREA VS HYDROXUREA + DDI VS DDI$124,146
M01 · FY2001 · RR
ACTG 364--COMPARISON OF THE VIROLOGIC EFFICACY OF NELFINAVIR$0
M01 · FY2001 · RR
LODENOSINE (FDDA) COMBINED W STAVUDINE &INDINAVIR$0
M01 · FY2001 · RR
ACTG 307--HYDROXUREA VS HYDROXUREA + DDI VS DDI$0
M01 · FY2001 · RR
ACTG 5025: HYDROXYUREA IN PTS ON POTENT ANTIRETROVIRAL$0
M01 · FY2001 · RR
ACTG 384: STUDY OF PROTEASE INHIBITOR AND/OR NON NUCLEOSIDE REVERSE$0
M01 · FY2001 · RR
ACTG A5039: HIV RNA SUPPRESSION DDL/D4T/HU VS DDL/D4TEPV VS CONTINUING PROTEASE$0
M01 · FY2001 · RR
GS-417: EFFICACY OF ADEFOVIR DIPIVOXIL AT 2 DOSE LEVELS IN TRIPLE COMBINATION$0
M01 · FY2001 · RR
ACTG 325: RECOMBINANT HUMAN INTERLEUKIN 12 (RHIL 12) IN HIV INFECTED SUBJECTS$0
M01 · FY2001 · RR
ACTG374: STUDY 1) 141W94 &VX 478 PLUS 3TC PLUS ZDV OR 2) INDINAVIR +$0
M01 · FY2001 · RR
ACTG248--SUBCUTANEOUS INTERLEUKIN 2 COMBINED WITH ANTIRETROVIRAL THERAPY$187,536
M01 · FY2000 · RR
ANTIRETROVIRAL NAIVE SUBJECTS WITH CD4 CELL COUNTS OF 200-700/MM3$187,536
M01 · FY2000 · RR
ACTG347--RANDOMIZED DOUBLE BLIND PHASE II STUDY OF 141W94/VX478 MONOTHERAPY$187,536
M01 · FY2000 · RR
ACTG248--SUBCUTANEOUS INTERLEUKIN 2 COMBINED WITH ANTIRETROVIRAL THERAPY$187,536
M01 · FY2000 · RR
ANTIRETROVIRAL NAIVE SUBJECTS WITH CD4 CELL COUNTS OF 200-700/MM3$187,536
M01 · FY2000 · RR
ACTG347--RANDOMIZED DOUBLE BLIND PHASE II STUDY OF 141W94/VX478 MONOTHERAPY$187,536
M01 · FY2000 · RR
ACTG248--SUBCUTANEOUS INTERLEUKIN 2 COMBINED WITH ANTIRETROVIRAL THERAPY$25,114
M01 · FY2000 · RR
ACTG 307--HYDROXUREA VS HYDROXUREA + DDI VS DDI$25,114
M01 · FY2000 · RR
ACTG 384: STUDY OF PROTEASE INHIBITOR AND/OR NON NUCLEOSIDE REVERSE$25,114
M01 · FY2000 · RR
ACTG 325: RECOMBINANT HUMAN INTERLEUKIN 12 (RHIL 12) IN HIV INFECTED SUBJECTS$25,114
M01 · FY2000 · RR
ACTG374: STUDY 1) 141W94 &VX 478 PLUS 3TC PLUS ZDV OR 2) INDINAVIR +$25,114
M01 · FY2000 · RR
ACTG 364--COMPARISON OF THE VIROLOGIC EFFICACY OF NELFINAVIR$25,114
M01 · FY2000 · RR
GS-417: EFFICACY OF ADEFOVIR DIPIVOXIL AT 2 DOSE LEVELS IN TRIPLE COMBINATION$25,114
M01 · FY2000 · RR
ANTIRETROVIRAL NAIVE SUBJECTS WITH CD4 CELL COUNTS OF 200-700/MM3$25,114
M01 · FY2000 · RR
ACTG347--RANDOMIZED DOUBLE BLIND PHASE II STUDY OF 141W94/VX478 MONOTHERAPY$25,114
M01 · FY2000 · RR
ACTG A5039: HIV RNA SUPPRESSION DDL/D4T/HU VS DDL/D4TEPV VS CONTINUING PROTEASE$0
M01 · FY2000 · RR
ACTG374: STUDY 1) 141W94 &VX 478 PLUS 3TC PLUS ZDV OR 2) INDINAVIR +$0
M01 · FY2000 · RR
ACTG374: STUDY 1) 141W94 &VX 478 PLUS 3TC PLUS ZDV OR 2) INDINAVIR +$0
M01 · FY2000 · RR
ACTG A5039: HIV RNA SUPPRESSION DDL/D4T/HU VS DDL/D4TEPV VS CONTINUING PROTEASE$0
M01 · FY2000 · RR
LODENOSINE (FDDA) COMBINED W STAVUDINE &INDINAVIR$0
M01 · FY2000 · RR
ACTG 364--COMPARISON OF THE VIROLOGIC EFFICACY OF NELFINAVIR$0
M01 · FY2000 · RR
ACTG 364--COMPARISON OF THE VIROLOGIC EFFICACY OF NELFINAVIR$0
M01 · FY2000 · RR
GS-417: EFFICACY OF ADEFOVIR DIPIVOXIL AT 2 DOSE LEVELS IN TRIPLE COMBINATION$0
M01 · FY2000 · RR
GS-417: EFFICACY OF ADEFOVIR DIPIVOXIL AT 2 DOSE LEVELS IN TRIPLE COMBINATION$0
M01 · FY2000 · RR
ACTG A5039: HIV RNA SUPPRESSION DDL/D4T/HU VS DDL/D4TEPV VS CONTINUING PROTEASE$0
M01 · FY2000 · RR
ACTG 307--HYDROXUREA VS HYDROXUREA + DDI VS DDI$0
M01 · FY2000 · RR
ACTG 307--HYDROXUREA VS HYDROXUREA + DDI VS DDI$0
M01 · FY2000 · RR
ACTG 5025: HYDROXYUREA IN PTS ON POTENT ANTIRETROVIRAL$0
M01 · FY2000 · RR
LODENOSINE (FDDA) COMBINED W STAVUDINE &INDINAVIR$0
M01 · FY2000 · RR
ACTG 5025: HYDROXYUREA IN PTS ON POTENT ANTIRETROVIRAL$0
M01 · FY2000 · RR
ACTG 5025: HYDROXYUREA IN PTS ON POTENT ANTIRETROVIRAL$0
M01 · FY2000 · RR
ACTG 384: STUDY OF PROTEASE INHIBITOR AND/OR NON NUCLEOSIDE REVERSE$0
M01 · FY2000 · RR
ACTG 384: STUDY OF PROTEASE INHIBITOR AND/OR NON NUCLEOSIDE REVERSE$0
M01 · FY2000 · RR
LODENOSINE (FDDA) COMBINED W STAVUDINE &INDINAVIR$0
M01 · FY2000 · RR
ACTG 325: RECOMBINANT HUMAN INTERLEUKIN 12 (RHIL 12) IN HIV INFECTED SUBJECTS$0
M01 · FY2000 · RR
ACTG 325: RECOMBINANT HUMAN INTERLEUKIN 12 (RHIL 12) IN HIV INFECTED SUBJECTS$0
M01 · FY2000 · RR